Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy.
Carcinoma
albumin-bilirubin (ALBI)
hepatectomy
hepatocellular
prognosis
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
27
9
2019
pubmed:
27
9
2019
medline:
27
9
2019
Statut:
ppublish
Résumé
The albumin-bilirubin (ALBI) grade is an index that could objectively evaluate liver function. The purpose of this study was to evaluate the prognostic value of postoperative ALBI (post-ALBI) grade and ALBI changes (△ALBI) after hepatectomy in patients with hepatocellular carcinoma (HCC). The clinical and pathological data of 300 patients with HCC who underwent hepatectomy in the Third Affiliated Hospital of Sun Yat-Sen University from January 19, 2009 to December 25, 2014, were analyzed retrospectively. According to the test data, the patients were divided into post-ALBI grade I, post-ALBI grade II, and post-ALBI grade III groups. According to the receiver operating characteristic curves (ROC), the patients were divided into △ALBI (△ALBI >0.71) high and low groups (△ALBI ≤0.71). Baseline clinical data, recurrence-free survival (RFS) and overall survival (OS) rates were compared between the groups. The 1-, 3-, and 5-year RFS rates and OS rates of patients with post-ALBI grade III were significantly reduced in comparison to those with post-ALBI grade II (P<0.001 both). Between the △ALBI groups, patients with low △ALBI level had significantly reduced 1-, 3-, and 5-year RFS rates and OS rates compared to those with a high △ALBI level (P<0.001 both). Multivariate analyses indicated that higher post-ABLI grade and △ALBI level were significantly independent predictors of an inferior OS and RFS (P<0.05). This study confirmed for the first time that post-ALBI grade and △ALBI could predict the prognosis of patients with HCC after hepatectomy.
Sections du résumé
BACKGROUND
BACKGROUND
The albumin-bilirubin (ALBI) grade is an index that could objectively evaluate liver function. The purpose of this study was to evaluate the prognostic value of postoperative ALBI (post-ALBI) grade and ALBI changes (△ALBI) after hepatectomy in patients with hepatocellular carcinoma (HCC).
METHODS
METHODS
The clinical and pathological data of 300 patients with HCC who underwent hepatectomy in the Third Affiliated Hospital of Sun Yat-Sen University from January 19, 2009 to December 25, 2014, were analyzed retrospectively. According to the test data, the patients were divided into post-ALBI grade I, post-ALBI grade II, and post-ALBI grade III groups. According to the receiver operating characteristic curves (ROC), the patients were divided into △ALBI (△ALBI >0.71) high and low groups (△ALBI ≤0.71). Baseline clinical data, recurrence-free survival (RFS) and overall survival (OS) rates were compared between the groups.
RESULTS
RESULTS
The 1-, 3-, and 5-year RFS rates and OS rates of patients with post-ALBI grade III were significantly reduced in comparison to those with post-ALBI grade II (P<0.001 both). Between the △ALBI groups, patients with low △ALBI level had significantly reduced 1-, 3-, and 5-year RFS rates and OS rates compared to those with a high △ALBI level (P<0.001 both). Multivariate analyses indicated that higher post-ABLI grade and △ALBI level were significantly independent predictors of an inferior OS and RFS (P<0.05).
CONCLUSIONS
CONCLUSIONS
This study confirmed for the first time that post-ALBI grade and △ALBI could predict the prognosis of patients with HCC after hepatectomy.
Identifiants
pubmed: 31555681
doi: 10.21037/atm.2019.06.01
pii: atm-07-16-367
pmc: PMC6736828
doi:
Types de publication
Journal Article
Langues
eng
Pagination
367Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
J Am Coll Surg. 2000 May;190(5):574-9
pubmed: 10801024
J Clin Oncol. 2001 Jun 15;19(12):3037-44
pubmed: 11408499
J Hepatol. 2003 Feb;38(2):200-7
pubmed: 12547409
J Hepatol. 2005;42 Suppl(1):S100-7
pubmed: 15777564
Surgery. 2007 Mar;141(3):330-9
pubmed: 17349844
Hepatol Int. 2010 Mar 18;4(2):439-74
pubmed: 20827404
J Gastroenterol Hepatol. 2011 Dec;26(12):1765-71
pubmed: 21615793
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Eur J Surg Oncol. 2012 Apr;38(4):286-95
pubmed: 22281155
HPB (Oxford). 2012 May;14(5):285-90
pubmed: 22487065
Scand J Gastroenterol. 2014 Jun;49(6):649-61
pubmed: 24716523
Am J Surg. 2015 Jan;209(1):199-205
pubmed: 25312843
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Invest New Drugs. 2015 Dec;33(6):1257-62
pubmed: 26462681
J Gastroenterol Hepatol. 2016 May;31(5):1031-6
pubmed: 26647219
Br J Surg. 2016 May;103(6):725-734
pubmed: 27005482
Clin Chim Acta. 2016 Nov 1;462:15-22
pubmed: 27520748
J Hepatol. 2017 Feb;66(2):338-346
pubmed: 27677714
Hepatol Res. 2017 Nov;47(12):1289-1298
pubmed: 28169483
J Gastroenterol Hepatol. 2017 Dec;32(12):1975-1981
pubmed: 28295594
Cell Physiol Biochem. 2017;44(3):967-981
pubmed: 29179180
Cell Physiol Biochem. 2018;48(1):317-327
pubmed: 30016765